Conference Day 1

Explore our agenda to see all sessions, timings, and full speaker details for the 2021 Gastrointestinal Cancer Drug Development Summit.

This event has now run.

8:00 am Online Networking Coffee

8:45 am Chair’s Opening Remarks

  • Thomas Tan Chief Scientific Officer, Immunitas Therapeutics

8:50 am Panel Discussion: A Brief History – Why Haven’t Advancements in Targeted- & Immunotherapies Had More Impact on GI Cancers?


  • With many promising candidates in targeted and immunotherapy simply not meeting expectations, where should we be looking?
  • Understanding and translation of the pathologies of various GI cancers: MSS vs MSI CRC, HCC, PDAC & more
  • Where is the field moving? Which tumors to focus certain therapeutics on?
  • How will early detection, precision oncology & patient groups mould this landscape?

Identifying & Advancing Promising Solid Tumor Therapeutics to Pursue in GI Cancer Indications

9:00 am Considerations for Pursuing GI Cancer Indications: Concept, Implementation & Clinical Results

  • Edward Cha Global Development Lead, GI CANCERS & COMBINATIONS, Genentech

9:30 am TGF-β Signature is a Therapeutic Biomarker for Combination Immunotherapy for Hepatocellular Carcinoma

  • Jian Chen Director, Translational Research and Preclinical Development, BioAtla

10:00 am Virtual Speed Networking Break

Developing a Clinical Program for Targeted Therapy to Advance Your Drug

10:30 am Targeting KRAS Mutant Colorectal Cancer with a KRAS G12C Inhibitor: Current Status and Future Questions

  • Linh Alejandro Medical Affairs Strategy GI Lead, Mirati Therapeutics Inc.


  • History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C in CRC
  • Clinical progress of KRAS G12C inhibitors (e.g. adagrasib) and treatment of patients with KRAS G12C mutated CRC
  • Future questions and directions for targeting KRAS G12C in CRC, including combination strategies

11:00 am NRG1 fusions: A Tumor-Agnostic Oncogenic Driver

  • Valerie Jansen Vice President - Clinical Development, Elevation Oncology


  • Genomic alterations fall on a spectrum of oncogenic potential. Oncogenic driver alterations are optimal biomarkers for targeted therapy development in precision oncology
  • NRG1 fusions are emerging as potentially actionable oncogenic driver alterations that can be found across solid tumors and may be enriched in certain GI cancers such as pancreatic ductal adenocarcinoma (PDAC)
  • NRG1 fusions may be therapeutically actionable through inhibition of HER3 with mAbs such as seribantumab, currently being investigated in the Phase 2 tumor-agnostic CRESTONE trial (NCT04383210)

11:30 am Novel Combination Therapy Approach To Targeting Immune Resistance in Colorectal Cancer

  • Harish Dave Co-Founder & Chief Medical Officer, AUM Biosciences

12:00 pm Online Networking Lunch

1:00 pm T Cell Engaging Bispecific Antibodies for Treatment of Solid Tumors


  • Bispecific T cell engaging antibodies redirect the immune system to target TAA+ cells
  • Our T cell engaging arm elicits potent cytotoxicity without high cytokine release
  • Our Discovery Platform allows for robust screening in a high-throughput manner of TAA specific UniAbs (fully human, heavy chain only antibodies) to identify candidates for the TAA arm of our bispecific antibodies

1:30 pm Numerous Applications of Stool Derived Eukaryotic RNA (seRNA) Biomarkers to Non-invasively Assess Gastrointestinal Disease


  • Improving detection, monitoring, and measurement of treatment response for patients with GI diseases, including CRC and IBD
  • Refining clinically relevant biomarker panels using eukaryotic RNA from gastrointestinal enterocytes, resident lymphocytes, and the hostmicrobiome interaction
  • Leveraging technology across a variety of biomarker types, including
    RNA expression, allele frequencies of expressed RNA variants, and
    protein concentrations

2:00 pm COBRA: Conditionally Active Bispecific T Cell Engager

  • Timothy Chen Director, Cell Biology, Maverick Therapeutics


  • Highly potent active drug moiety
  • Conditionally active only upon cleavage by proteases present in the TME
  • Potential for wide therapeutic window in treatment of solid tumors

Developing a Clinical Program for Immunotherapy in GI Tumors

2:30 pm Tumor Localized Immune Activation with PRS-343 (4-1BB-HER2 bispecific) – From Concept to Clinical Efficacy


  • Localized 4-1BB agonism leads to robust activation of T cells
  • PRS-343 is safe and well tolerated
  • PRS-343 shows clinical activity in Gastric Cancer patients (Phase 1 data)

3:00 pm Immuno-Oncology For Early Stage Disease

  • Rebecca A. Moss Clinical Development Lead, Oncology Clinical Development Relatlimab GI , Bristol-Myers Squibb


  • Efficacy of IO in late stage/metastatic disease
  • Translating late stage IO efficacy to the adjuvant setting: CheckMate-577 trial
  • Potential for Neoadjuvant IO therapies based on data from Melanoma and Lung cancer

3:30 pm Afternoon Networking Break

Drugging the Undruggable: PDAC

4:00 pm Development of KN046, a PD-L1/CTLA-4 Bispecific, for Pancreatic Cancer

  • Ting Xu Chairman, Chief Executive Offier, Executive Director & Founder, Alphamab Oncology


  • Design of KN046 to reduce on target toxicity
  • Dual ICI blocking demonstrated Significant anti-tumor activity with acceptable safety profile
  • Early but promising sign of clinical activity in 1st pancreatic cancer seen in phase II trial

4:30 pm Immunostimulatory Gene Therapy for Pancreatic Cancer – Clinical Data


  • LOAd703 is an oncolytic adenovirus encoding two human immunostimulatory genes, TMZ-CD40L and 4-1BBL
  • Immunostimulatory gene therapy using oncolytic viruses like LOAd703 can make immune “cold” tumors “hot”
  • LOAd703 show interesting clinical data as an combination treatment with standard of care chemotherapy

5:00 pm End of Conference Day 1